ArticleContraception2021
Expansion of a direct-to-patient telemedicine abortion service in the United States and experience during the COVID-19 pandemic.
Article in Contraception, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Telemedicine for the provision of medication abortion to pregnant people at up to twelve weeks of pregnancy: a systematic literature review and meta-analysis.Reproductive health · 2024Pooled it
- Abortion services during the COVID-19 pandemic: a systematic review.Reproductive health · 2023Pooled it
- Reasons for Choosing Telehealth Abortion Based on Food Insecurity Status: United States, 2021-2022.American journal of public health · 2026Article
- Effectiveness and safety of medication abortion with vs without screening ultrasonography or pelvic examination.American journal of obstetrics and gynecology · 2025Article
- Implementing telemedicine for medical abortion within the public health system: a qualitative study on implementation bottlenecks and solutions in South Africa.BMC public health · 2025Article
- Characteristics of people obtaining mifepristone and misoprostol and misoprostol-only telehealth medication abortion services in the United States.Contraception · 2025Article
- Perspectives on Abortion Services, the Pre-Abortion Visit, and Telemedicine Abortion: A Qualitative Study in Sweden.Perspectives on sexual and reproductive health · 2025Article
- First-trimester medication abortion via telemedicine: A retrospective cohort study.Public health in practice (Oxford, England) · 2024Article
- Perceptions and experiences with two no-test direct-to-patient telehealth medication abortion regimens in the USA: an exploratory study with mifepristone and misoprostol and misoprostol-only regimens.BMJ public health · 2024Article
- Abortion Training in Family Medicine Residency Programs: A National Survey of Program Directors 5 Months After the Dobbs Decision.Family medicine · 2024Article
- Effectiveness and safety of telehealth medication abortion in the USA.Nature medicine · 2024Article
- Patient Acceptability of Telehealth Medication Abortion Care in the United States, 2021‒2022: A Cohort Study.American journal of public health · 2024Article
- A qualitative exploration of the over-the-counter availability of oral contraceptive pills in Australia.PloS one · 2024Article
- The Role of Telehealth in Promoting Equitable Abortion Access in the United States: Spatial Analysis.JMIR public health and surveillance · 2023Article
- Medication abortion via digital health in the United States: a systematic scoping review.NPJ digital medicine · 2023Article
- "I'm going to be forced to have a baby": A study of COVID-19 abortion experiences on Reddit.Perspectives on sexual and reproductive health · 2023Article
- Mailing abortion pills does not delay care: A cohort study comparing mailed to in-person dispensing of abortion medications in the United States.Contraception · 2023Article
- Telemedicine for First-Trimester Medical Abortion in Canada: Results of a 2019 Survey.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2023Article
- Patient concerns about accessing sexual and reproductive health services outside of primary care: A survey in rural and urban settings in the Pacific Northwest.Contraception · 2023Article
- Abortion bans and their impacts: A view from the United States.Cell reports. Medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
objectiveTo present updated evidence on the safety, efficacy and acceptability of a direct-to-patient telemedicine abortion service and describe how the service functioned during the COVID-19 pandemic. STUDY
designWe offered the study at 10 sites that provided the service in 13 states and Washington DC. Interested individuals obtained any needed preabortion tests locally and had a videoconference with a study clinician. Sites sent study packages containing mifepristone and misoprostol by mail and had remote follow-up consultations within one month by telephone (or by online survey, if the participant could not be reached) to evaluate abortion completeness. The analysis was descriptive.
resultsWe mailed 1390 packages between May 2016 and September 2020. Of the 83% (1157/1390) of abortions for which we obtained outcome information, 95% (1103/1157) were completed without a procedure. Participants made 70 unplanned visits to emergency rooms or urgent care centers for reasons related to the abortion (6%), and 10 serious adverse events occurred, including 5 transfusions (0.4%). Enrollment increased substantially with the onset of COVID-19. Although a screening ultrasound was required, sites determined in 52% (346/669) of abortions that occurred during COVID that those participants should not get the test to protect their health. Use of urine pregnancy test to confirm abortion completion increased from 67% (144/214) in the 6 months prior to COVID to 90% (602/669) in the 6 months during COVID. Nearly all satisfaction questionnaires (99%, 1013/1022) recorded that participants were satisfied with the service.
conclusionsThis direct-to-patient telemedicine service was safe, effective, and acceptable, and supports the claim that there is no medical reason for mifepristone to be dispensed in clinics as required by the Food and Drug Administration. In some cases, participants did not need to visit any facilities to obtain the service, which was critical to protecting patient safety during the COVID-19 pandemic. IMPLICATIONS: Medical abortion using telemedicine and mail is effective and can be safely provided without a pretreatment ultrasound. This method of service delivery has the potential to greatly improve access to abortion care in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.